Current and future use of remdesivir in patients with COVID-19
https://doi.org/10.37489/2588-0519-2020-S4-99-102
Abstract
There are prerequisites for the use of remdesivir against SARS-CoV-2 in stationary conditions. Remdesivir is not registered in the Russian Federation. The preliminary results of randomized clinical trials on the efficacy of remission are contradictory.
About the Authors
V. M. Tsvetov
Federal Center for Cardiovascular Surgery of the Ministry of Health of Russia
Russian Federation
Russian Federation
Tsvetov Vitaly M. – Candidate of Medical Sciences, Doctor — Clinical Pharmacologist. SPIN code: 3202-7659
Chelyabinsk
K. B. Mirzaev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. Agostini ML, Andres EL, Sims AC et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018 Mar 6;9(2):e00221-18. DOI: 10.1128/mBio.00221-18
2. Sheahan TP, Sims AC, Graham RL et al. Broad-spectrum antiviral GS5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun 28;9(396):eaal3653. DOI: 10.1126/scitranslmed.aal3653
3. Sheahan TP, Sims AC, Leist SR et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. DOI: 10.1038/s41467-01913940-6
4. «Singapore approves remdesivir drug for emergency COVID-19 treatment». Reuters. Retrieved 10 June 2020.
5. Wang M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DOI: 10.1038/s41422-020-0282-0
6. FDA Allows For ‘Emergency Use’ of Remdesivir, Experimental Coronavirus Drug (англ.). TIME. ASSOCIATED PRESS (1 May 2020)
7. Herman Steve. Coronavirus Treatment Breakthrough Announced. Voice of America. [Internet]. [cited 2020 April 29]; Available from: https://www.voanews.com/covid-19-pandemic/coronavirus-treatment-breakthrough-announced
8. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. National Institute of Allergy and Infectious Diseases (NIAID) [Internet]. [cited 2020 April 29]; Available from: https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-acceleratesrecovery-advanced-covid-19
9. Voronin N. Scientists have confirmed the effectiveness of ramdevpir in the treatment of coronavirus. BBC News Russian service. (In Russ). [Электронный ресурс]. Доступно по: https://www.bbc.com/russian/news-52490929 Ссылка активна на 30.04.2020
10. Beigel JH et al. Remdesivir for the Treatment of Covid-19 Preliminary Report. N Engl J Med. 2020 May 22;NEJMoa2007764. DOI: 10.1056/NEJMoa2007764
11. Gøtzsche PC. Remdesivir against coronavirus, hope or hype? / Prof. Peter C. Gøtzsche — Copenhagen: Institute for Scientific Freedom [Internet]. [cited 2020 June 1]; Available from: https://www.scientificfreedom.dk/wpcontent/uploads/2020/06/Gøtzsche-Remdesivir-against-coronavirus-hopeor-hype.pdf
12. Goldman JD et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 May 27;NEJMoa2015301. DOI: 10.1056/NEJMoa2015301
13. Search of: Favipiravir — List Results — ClinicalTrials.gov [Internet]. [cited 2020 July 09]; Available from: https://clinicaltrials.gov/ct2/results?cond=&term=&type=&rslt=&age_v=&gndr=&intr=Remdesivir
14. World Health Organization (WHO) (2020) Clinical management of COVID-19. Interim Guidance. 27 May. [Internet]. [cited 2020 June 09]; Available from: https://www.who.int/publications/i/item/clinicalmanagement-of-covid-19
15. Frequently Asked Questions on the Emergency Use Authorization for Remdesivir for Certain Hospitalized COVID-19 Patients [Internet]. [cited 2020 June 09]; Available from: https://www.fda.gov/media/137574/download
16. Caroline Cassels. COVID-19 Update: Elusive Complication, Remdesivir Toxicity. Medscape Medical News. gov [Internet]. [cited 2020 July 08]; Available from: https://www.medscape.com/viewarticle/933623?src=iphone&ref=email#vp_1
17. The state register of medicinal products, registry of permits for the conduct of clinical trials [RCTS]. (In Russ). [Электронный ресурс]. Доступно по: https://grls.rosminzdrav.ru/CiPermitionReg.aspx?Torg=ремдесивир Ссылка активна на 09.07.2020
Review
For citations:
Tsvetov V.M., Mirzaev K.B., Sychev D.A. Current and future use of remdesivir in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):99-102. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-99-102
Views:
913
Email this article 